Gerald Grütz
YOU?
Author Swipe
View article: A complex osteoporotic milieu is associated with arterial stiffening and PDGF-BB-mediated calcification of human smooth muscle cells
A complex osteoporotic milieu is associated with arterial stiffening and PDGF-BB-mediated calcification of human smooth muscle cells Open
Accumulating evidence links skeletal and vascular aging, yet the pathological cross-talk between osteoporotic bone and vascular calcification remains insufficiently understood. In this retrospective exploratory study, we show that osteopor…
View article: ILOBONE: A phase I/IIa randomized controlled trial to assess the safety and feasibility of local iloprost therapy for enhancing proximal humerus fracture healing– a pilot study design
ILOBONE: A phase I/IIa randomized controlled trial to assess the safety and feasibility of local iloprost therapy for enhancing proximal humerus fracture healing– a pilot study design Open
View article: ILOBONE: A phase I/IIa randomized controlled trial to assess the safety and feasibility of local iloprost therapy for enhancing proximal humerus fracture healing – a pilot study design
ILOBONE: A phase I/IIa randomized controlled trial to assess the safety and feasibility of local iloprost therapy for enhancing proximal humerus fracture healing – a pilot study design Open
Background Proximal humerus fractures (PHFs) are the third most common fractures in elderly patients. Over 70% of PHFs in patients aged over 60 are displaced fractures, often necessitating surgical treatment. However, osteosynthesis is ass…
View article: Intestinal interstitial fluid isolation provides novel insight into the human host-microbiome interface
Intestinal interstitial fluid isolation provides novel insight into the human host-microbiome interface Open
Aims The gastrointestinal (GI) tract is composed of distinct sub-regions, which exhibit segment-specific differences in microbial colonization and (patho)physiological characteristics. Gut microbes can be collectively considered as an acti…
View article: Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis
Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis Open
NCT02282826, NCT02977533, NCT02313285.
View article: Intestinal interstitial fluid isolation provides novel insight into the human host-microbiome interface
Intestinal interstitial fluid isolation provides novel insight into the human host-microbiome interface Open
Aims The gastrointestinal (GI) tract is composed of distinct subregions which exhibit segment-specific differences in microbial colonization and (patho)physiological characteristics. Gut microbes can be collectively considered as an active…
View article: Validation of novel multiplex technologies
Validation of novel multiplex technologies Open
Cytokine and chemokine levels in body fluid provide information of altered conditions in patients. The parallel analysis of multiple factors, such as cytokines, from small sample sizes is an interesting approach for the assessment of in vi…
View article: Individual immune cell and cytokine profiles determine platelet-rich plasma composition
Individual immune cell and cytokine profiles determine platelet-rich plasma composition Open
View article: Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD
Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD Open
View article: Individual Immune Cell and Cytokine Profiles Impact Platelet-Rich Plasma Composition
Individual Immune Cell and Cytokine Profiles Impact Platelet-Rich Plasma Composition Open
Objective: Platelet-rich plasma (PRP) is increasingly popular to treat musculoskeletal diseases, including tendinopathies and osteoarthritis (OA). To date, it remains unclear to which extent PRP compositions are determined by the immune pr…
View article: Generation of HBsAg‐reactive T‐ and B‐cells following HBV vaccination in serological non‐responders under hemodialysis treatment
Generation of HBsAg‐reactive T‐ and B‐cells following HBV vaccination in serological non‐responders under hemodialysis treatment Open
HBV vaccination is recommend for hemodialysis patients, but only 50-60% of the patients show seroconversion. HBV vaccine-induced generation of HBV reactive T and B cells could be detected regardless of their capacity to mount a serological…
View article: Killer-like receptors and GPR56 progressive expression defines cytokine production of human CD4+ memory T cells
Killer-like receptors and GPR56 progressive expression defines cytokine production of human CD4+ memory T cells Open
View article: Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT‐ME‐1 trial
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT‐ME‐1 trial Open
TREAT‐ME‐1, a Phase 1/2 open‐label multicenter, first‐in‐human, first‐in‐class trial, evaluated the safety, tolerability and efficacy of treatment with genetically modified autologous mesenchymal stromal cells (MSC), MSC_ apceth_101, in co…
View article: Gravitational stress during parabolic flights reduces the number of circulating innate and adaptive leukocyte subsets in human blood
Gravitational stress during parabolic flights reduces the number of circulating innate and adaptive leukocyte subsets in human blood Open
Gravitational stress occurs during space flights or certain physical activities including extreme sports, where the change in experienced gravitational acceleration can reach large magnitudes. These changes include reduction and increase i…
View article: Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial Open
Treatment with MSC_apceth_101 in combination with GCV demonstrated acceptable safety and tolerability in patients with advanced gastrointestinal adenocarcinoma.